Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | ITGB1 | P05556 | 4/20 | 0.41 |
| ▸ | ITGA4 | P13612 | 4/20 | 0.41 |
| ▸ | MAOB | P27338 | 3/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | EPHB3 | P54753 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL92363 | 0.92 | ITGB1 (0.42) | ITGB1ITGA4MAOBNR4A2LMNA | |
| SCHEMBL10285851 | 0.91 | RAB9A (0.43) | RAB9ASMN1; SMN2NPC1ITGB1ITGA4 | |
| SCHEMBL93044 | 0.90 | RAB9A (0.46) | RAB9ASMN1; SMN2NPC1ITGB1ITGA4 | |
| SCHEMBL10273947 | 0.90 | NR4A2 (0.43) | RAB9ASMN1; SMN2NPC1MAOBNR4A2 | |
| SCHEMBL91603 | 0.89 | MAOB (0.51) | RAB9ANPC1ITGB1ITGA4MAOB | |
| SCHEMBL93049 | 0.86 | RAB9A (0.59) | RAB9ASMN1; SMN2NPC1MAOBNR4A2 | |
| SCHEMBL92496 | 0.85 | MAPT (0.42) | ITGB1ITGA4MAOBLMNAPOLB | |
| SCHEMBL91539 | 0.84 | MAPT (0.42) | RAB9ASMN1; SMN2NPC1ITGB1ITGA4 | |
| SCHEMBL92572 | 0.81 | ALDH1A1 (0.44) | RAB9AITGB1ITGA4MAOBLMNA | |
| SCHEMBL92573 | 0.81 | PCSK9 (0.42) | RAB9AITGB1ITGA4MAOBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130065882-A1 | VLA-4 inhibitory drug | MACHINAGA NOBUO (JP) | 2013-03-14 | — | — | US | disclosed |
| US-20120157437-A1 | VLA-4 INHIBITORY DRUG | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-06-21 | — | — | US | disclosed |
| US-8129366-B2 | VLA-4 inhibitory drug | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-03-06 | — | — | US | disclosed |
| US-20090233901-A1 | VLA-4 INHIBITORY DRUG | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157437-A1 | VLA-4 INHIBITORY DRUG | VCAM1, ITGB4, ITGA4 | RAB9A 1503/4885SMN1; SMN2 4739/4885NPC1 680/4885 |
| US-20130065882-A1 | VLA-4 inhibitory drug | VCAM1, ITGB4, ITGA4 | RAB9A 1491/4885SMN1; SMN2 4702/4885NPC1 551/4885 |
| US-20090233901-A1 | VLA-4 INHIBITORY DRUG | VCAM1, ITGB4, ITGA4 | RAB9A 1187/4885SMN1; SMN2 4787/4885NPC1 624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.